GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (NAS:KTRA) » Definitions » Asset Turnover

Kintara Therapeutics (Kintara Therapeutics) Asset Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Kintara Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Kintara Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Kintara Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $1.68 Mil. Therefore, Kintara Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Kintara Therapeutics's annualized ROE % for the quarter that ended in Dec. 2023 was 373.70%. It is also linked to ROA % through Du Pont Formula. Kintara Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -243.43%.


Kintara Therapeutics Asset Turnover Historical Data

The historical data trend for Kintara Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Asset Turnover Chart

Kintara Therapeutics Annual Data
Trend Dec13 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kintara Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kintara Therapeutics's Asset Turnover

For the Biotechnology subindustry, Kintara Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintara Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's Asset Turnover falls into.



Kintara Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Kintara Therapeutics's Asset Turnover for the fiscal year that ended in Jun. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Jun. 2023 )/( (Total Assets (A: Jun. 2022 )+Total Assets (A: Jun. 2023 ))/ count )
=0/( (15.948+3.979)/ 2 )
=0/9.9635
=0.00

Kintara Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (1.477+1.885)/ 2 )
=0/1.681
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Kintara Therapeutics  (NAS:KTRA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Kintara Therapeutics's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-4.092/-1.095
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-4.092 / 0)*(0 / 1.681)*(1.681/ -1.095)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-1.5352
=ROA %*Equity Multiplier
=-243.43 %*-1.5352
=373.70 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Kintara Therapeutics's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-4.092/1.681
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-4.092 / 0)*(0 / 1.681)
=Net Margin %*Asset Turnover
= %*0
=-243.43 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Kintara Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintara Therapeutics (Kintara Therapeutics) Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
Executives
Robert Hoffman director, officer: President and CEO ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Anthony Scott Praill officer: Chief Financial Officer 2001-889 HOMER STREET, VANCOUVER A1 V6B 5S3
Saiid Zarrabian director, officer: Head of Strategic Partnerships P.O. BOX 675765, RANCHO SANTA FE CA 92067
Laura L. Johnson director C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Tamara A Seymour director C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Toth Robert Joseph Jr director 543 LOMBARD ST, SAN FRANCISCO CA 94133
Dennis M Brown officer: Chief Scientific Officer 100 SAN MATEO DR, MENLO PARK CA 94025
Keith Murphy director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
John Liatos director, officer: SVP, Business Development 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
John K Bell director 38 FALLBROOK LANE RR 33, CAMBRIDGE A6 N3H 4R8
Napoleone Ferrara director 550 FRONT STREET, UNIT 1103, SAN DIEGO CA 92101
Lynda Sarah Cranston director 4316 LOCARNO CRESCENT, VANCOUVER A1 V6R 1G3
Erich Mohr director 8300 GREENSBORO DRIVE, MCLEAN VA 22102
Jeffrey Bacha director SUITE 3 1545 WEST 14TH AVENUE, VANCOUVER A1 V6J 2J1
William J Garner director 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010